8-K: Coya Therapeutics Advances ALS Trial, Secures FDA Fast Track

Coya Therapeutics reported Q2 2026 results, noting progress in its ALSTARS Phase 2 ALS trial, FDA Fast Track designation for COYA 302, and plans for a new FTD study, while managing a net loss of $6.6 million.

Summary

• Coya Therapeutics announced its financial results for the second quarter ended June 30, 2026.
• The company is advancing its lead program, COYA 302, with enrollment in the ALSTARS Phase 2 ALS trial proceeding as planned.
• Enrollment for the ALSTARS trial is expected to be completed in the second half of 2026, with topline data anticipated in Q1 2027.
• A Phase 2 study of COYA 302 in frontotemporal dementia (FTD) is planned to initiate in the coming months.
• The company received FDA Fast Track Designation for COYA 302 for the treatment of ALS.
• As of June 30, 2026, Coya had $43.2 million in cash and cash equivalents, projected to fund operations past the ALSTARS topline data readout and into the second half of 2027.
• Collaboration revenue was $0.2 million for the quarter.
• Research and development expenses increased to $5.0 million, primarily due to the advancement of the COYA 302 ALS Phase 2 clinical trial.
• General and administrative expenses decreased to $2.3 million.
• The net loss for the quarter was $6.6 million, compared to $6.1 million in the prior year period.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive report, highlighting significant clinical trial progress and regulatory advancements, balanced by an increasing net loss and ongoing R&D investment.

Positives

• Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned and on track for completion in 2H 2026.
• FDA Fast Track Designation received for COYA 302 for the treatment of ALS, potentially expediting development and review.
• A new Phase 2 study for COYA 302 in frontotemporal dementia (FTD) is planned to initiate in the coming months.
• Cash and cash equivalents of $43.2 million are sufficient to fund operations past the Phase 2 ALSTARS topline data readout and into the second half of 2027.
• General and administrative expenses decreased by $0.6 million to $2.3 million.
• Publication in Annals of Clinical and Translational Neurology supporting the mechanistic rationale for COYA 302 in ALS patients.
• Scientific presentations delivered on the ALSTARS Phase 2 clinical trial design at industry conferences.
• Appointment of Mark H. Pavao as Independent Director.

Negatives

• Net loss increased to $6.6 million for the three months ended June 30, 2026, from $6.1 million in the prior year period.
• Research and development expenses increased by $1.3 million to $5.0 million, reflecting increased clinical trial costs.
• Net loss per share of common stock was $(0.28) for the quarter, compared to $(0.36) in the prior year period, indicating a wider loss on a per-share basis due to increased shares outstanding.

Risks

• The company's product candidates are investigational and not yet approved by the FDA or any other regulatory agency.
• Forward-looking statements are subject to known and unknown risks and uncertainties, including those discussed in the company's SEC filings, which could cause actual results to differ from expectations.
• The company's ability to advance its product candidates through preclinical and clinical development processes is subject to risks and uncertainties.
• The timing and availability of data from clinical trials are subject to potential delays and uncertainties.

Future Outlook

The company expects to complete enrollment in the ALSTARS Phase 2 trial in 2H 2026 and initiate a Phase 2 study of COYA 302 in FTD in the coming months. Topline data from the ALSTARS trial is anticipated in Q1 2027. Additional biomarker and in vivo data are also expected in 2H 2026.

Management Comments

• "During the second quarter, we made notable progress advancing our lead program, COYA 302," said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya.
• "Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027."
• "At the same time, we plan to initiate a Phase 2 study of COYA 302 in frontotemporal dementia (FTD) in the coming months."
• "Together, these programs reflect our differentiated strategy of applying Treg biology to address the shared mechanisms of these neurodegenerative conditions."
• "The progress we have made in the ALSTARS trial continues to reinforce our confidence in COYA 302 as we advance this program for people living with ALS," said Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya.
• "The blinded extension phase of the ALSTARS trial is now well underway. We are grateful to the patients, families, and investigators whose partnership makes this work possible."

Industry Context

StockSavvy.ai notes that Coya Therapeutics operates in the highly competitive and capital-intensive biotechnology sector, focusing on neurodegenerative diseases. The FDA Fast Track Designation for COYA 302 is a significant positive, potentially accelerating market entry if clinical trials prove successful. The company's strategy of applying Treg biology to neurodegenerative conditions aligns with emerging trends in immunology and neurology, though it faces challenges common to early-stage biotechs, including high R&D costs and clinical trial risks.

Management Changes

Stakeholder Impact

• Shareholders: The progress in clinical trials and FDA designation may positively influence future stock performance, but the increasing net loss and ongoing R&D investment represent continued financial risk.
• Patients: Advancements in COYA 302 for ALS and potential FTD treatment offer hope for new therapeutic options.
• Investigators and Clinical Sites: Continued progress in trials provides ongoing research opportunities and potential for future collaborations.
• Suppliers: Increased R&D activities may lead to higher demand for preclinical and clinical services and supplies.

Next Steps

• Complete enrollment in the ALSTARS Phase 2 trial in 2H 2026.
• Initiate a Phase 2 study evaluating COYA 302 for the treatment of FTD in 2H 2026.
• Announce biomarker data from the completed investigator-initiated study in patients with FTD in 2H 2026.
• Report additional single-cell proteomics data from completed ALS and AD investigator-initiated trials in 2H 2026.
• Publish in vivo data on COYA 303 in an inflammatory animal model in 2H 2026.
• Report topline data from the ALSTARS Phase 2 ALS trial in Q1 2027.

Key Dates

Recommendation

The company is making significant clinical progress with its lead candidate, COYA 302, evidenced by trial enrollment and FDA Fast Track designation. However, the increasing net loss and the long timeline to potential market approval, with topline data not expected until Q1 2027, warrant a cautious 'hold' stance. Investors should monitor trial results and cash runway closely.

Keywords

COYA 302, ALS, FTD, neurodegenerative disorders, Treg biology, Phase 2 trial, biotechnology, FDA Fast Track